Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage

Journal of General Virology

Volumn 96, Issue 8, 2015, Pages 2061-2073

  van de Sandt, Carolien E ^a   Dou, YingYing ^a   Vogelzang van Trierum, Stella E ^a   Westgeest, Kim B ^a   Pronk, Mark R ^a   Osterhaus, Albert D M E ^a,b   Fouchier, Ron A M ^a   Rimmelzwaan, Guus F ^a,b   Hillaire, Marine L B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Viroclinics Biosciences BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; VIRAL PROTEIN; VIRUS ANTIBODY;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; HLA SYSTEM; HUMAN; HUMAN CELL; INFLUENZA B; INFLUENZA B VIRUS; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; PHYLOGENETIC TREE; PREDICTION; PRIORITY JOURNAL; VIRUS CHARACTERIZATION; ADOLESCENT; ADULT; CHEMISTRY; CLASSIFICATION; FEMALE; GENETICS; IMMUNOLOGY; INFLUENZA; MALE; MIDDLE AGED; MOLECULAR GENETICS; PHYLOGENY; SEQUENCE HOMOLOGY; VIROLOGY; YOUNG ADULT;

INFLUENZA A VIRUS; INFLUENZA B VIRUS;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL PROTEINS; YOUNG ADULT;

EID: 84940208470     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.000156     Document Type: Article

References (84)

1. Altenburg, A. F., Kreijtz, J. H., de Vries, R. D., Song, F., Fux, R., Rimmelzwaan, G. F., Sutter, G. & Volz, A. (2014). Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735-2761.
2. Ambrose, C. S. & Levin, M. J. (2012). The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8, 81-88.
3. Antrobus, R. D., Berthoud, T. K., Mullarkey, C. E., Hoschler, K., Coughlan, L., Zambon, M., Hill, A. V. & Gilbert, S. C. (2014). Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther 22, 233-238.
4. Assarsson, E., Bui, H. H., Sidney, J., Zhang, Q., Glenn, J., Oseroff, C., Mbawuike, I. N., Alexander, J. & Newman, M. J. (2008). Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82, 12241-12251.
5. Belshe, R. B. (2010). The need for quadrivalent vaccine against seasonal influenza. Vaccine 28 (Suppl 4), D45-D53.
6. Belshe, R. B., Coelingh, K., Ambrose, C. S., Woo, J. C. & Wu, X. (2010). Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 28, 2149-2156.
7. Beran, J., Wertzova, V., Honegr, K., Kaliskova, E., Havlickova, M., Havlik, J., Jirincova, H., Van Belle, P. & Jain, V. (2009). Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 9, 2.
8. Berthoud, T. K., Hamill, M., Lillie, P. J., Hwenda, L., Collins, K. A., Ewer, K. J., Milicic, A., Poyntz, H. C. & Lambe, T. (2011). Potent CD8+T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52, 1-7.
9. Bodewes, R., Morick, D., deMutsert, G., Osinga, N., Bestebroer, T., vanderVliet, S., Smits, S. L., Kuiken, T. & Rimmelzwaan, G. F. (2013). Recurring influenza B virus infections in seals. Emerg Infect Dis 19, 511-512.
10. Boon, A. C., de Mutsert, G., Graus, Y. M., Fouchier, R. A., Sintnicolaas, K., Osterhaus, A. D. & Rimmelzwaan, G. F. (2002). The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. J Virol 76, 582-590.
11. Boon, A. C., De Mutsert, G., Fouchier, R. A., Sintnicolaas, K., Osterhaus, A. D. & Rimmelzwaan, G. F. (2004). Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 172, 4435-4443.
12. Boyce, W. M., Sandrock, C., Kreuder-Johnson, C., Kelly, T. & Cardona, C. (2009). Avian influenza viruses in wild birds: a moving target. Comp Immunol Microbiol Infect Dis 32, 275-286.
13. CDC (2009). Update: influenza activity - United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 58, 369-374.
14. CDC (2013). Prevention and controlof seasonal influenzawith vaccines. Recommendations of the Advisory Committee on Immunization Practices United States, 2013-2014. MMWR Recomm Rep 62 (RR- 07),1-43.
15. CDC (2014). Past weekly surveillance reports. http://www.cdc.gov/flu/ weekly/pastreports.htm
16. Chen, R. & Holmes, E. C. (2008). The evolutionary dynamics of human influenza B virus. J Mol Evol 66, 655-663.
17. Chen, J. M., Guo, Y. J., Wu, K. Y., Guo, J. F., Wang, M., Dong, J., Zhang, Y., Li, Z. & Shu, Y. L. (2007). Exploration of the emergence of the Victoria lineage of influenza B virus. Arch Virol 152, 415-422.
18. Daemen, T., de Mare, A., Bungener, L., de Jonge, J., Huckriede, A. & Wilschut, J. (2005). Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 57, 451-463.
19. Darriba, D., Taboada, G. L., Doallo, R. & Posada, D. (2012). jModelTest 2: more models, new heuristics and parallel computing. Nat Methods 9, 772.
20. Domachowske, J. B., Pankow-Culot, H., Bautista, M., Feng, Y., Claeys, C., Peeters, M., Innis, B. L. & Jain, V. (2013). A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 207,1878-1887.
21. Dreyfus, C., Laursen, N. S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D. C., Lee, J. H., Metlagel, Z. & Bujny, M. V. (2012). Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348.
22. Epstein, S. L. (2006). Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193, 49-53.
23. FDA (2012). FDA News Release: FDA approves first quadrivalent vaccine to prevent seasonal influenza. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm
24. Feng, L., Shay, D. K., Jiang, Y., Zhou, H., Chen, X., Zheng, Y., Jiang, L., Zhang, Q. & Lin, H. (2012). Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008. Bull World Health Organ 90, 279-288B.
25. Fiore, A. E., Uyeki, T. M., Broder, K., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M. & Shay, D. K. (2010). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59 (RR-8), 1-62.
26. Flynn, K. J., Belz, G. T., Altman, J. D., Ahmed, R., Woodland, D. L. & Doherty, P. C. (1998). Virus-specific CD8+T cells in primary and secondary influenza pneumonia. Immunity 8, 683-691.
27. Gao, R., Cao, B., Hu, Y., Feng, Z., Wang, D., Hu, W., Chen, J., Jie, Z. & Qiu, H. (2013). Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 368, 1888-1897.
28. Guindon, S. & Gascuel, O. (2003). A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst Biol 52, 696-704.
29. Guindon, S., Dufayard, J. F., Lefort, V., Anisimova, M., Hordijk, W. & Gascuel, O. (2010). New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59, 307-321.
30. Hall, T. A. (1999). BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41, 95-98.
31. He, X. S., Holmes, T. H., Zhang, C., Mahmood, K., Kemble, G. W., Lewis, D. B., Dekker, C. L., Greenberg, H. B. & Arvin, A. M. (2006). Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80, 11756-11766.
32. Heikkinen, T., Ikonen, N. & Ziegler, T. (2014). Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clin Infect Dis 59, 1519-1524.
33. Heinonen, S., Silvennoinen, H., Lehtinen, P., Vainionpaa¨, R., Ziegler, T. & Heikkinen, T. (2011). Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 11, 23-29.
34. Hillaire, M. L., van Trierum, S. E., Kreijtz, J. H., Bodewes, R., Geelhoed-Mieras, M. M., Nieuwkoop, N. J., Fouchier, R. A., Kuiken, T., Osterhaus, A. D. & Rimmelzwaan, G. F. (2011). Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 92, 2339-2349.
35. Hillaire, M. L., Vogelzang-van Trierum, S. E., Kreijtz, J. H., de Mutsert, G., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. (2013). Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple- reassortant H3N2 influenza viruses. J Gen Virol 94, 583-592.
36. Hoft, D. F., Babusis, E., Worku, S., Spencer, C. T., Lottenbach, K., Truscott, S. M., Abate, G., Sakala, I. G. & Edwards, K. M. (2011). Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 204, 845-853.
37. Jameson, J., Cruz, J. & Ennis, F. A. (1998). Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72, 8682-8689.
38. Jameson, J., Cruz, J., Terajima, M. & Ennis, F. A. (1999). Human CD8+ and CD4+T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162, 7578-7583.
39. Kieninger, D., Sheldon, E., Lin, W. Y., Yu, C. J., Bayas, J. M., Gabor, J. J., Esen, M., Fernandez Roure, J. L. & Narejos Perez, S. (2013). Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ¢18 years. BMC Infect Dis 13, 343.
40. Kimura, M. (1981). Estimation of evolutionary distances between homologous nucleotide sequences. Proc Natl Acad Sci U S A 78, 454-458.
41. Koel, B. F., Burke, D. F., Bestebroer, T. M., van der Vliet, S., Zondag, G. C., Vervaet, G., Skepner, E., Lewis, N. S. & Spronken, M. I. (2013). Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342, 976-979.
42. Kreijtz, J. H., Bodewes, R., van Amerongen, G., Kuiken, T., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. (2007). Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612-620.
43. Kreijtz, J. H., de Mutsert, G., van Baalen, C. A., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. (2008). Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82, 5161-5166.
44. Kreijtz, J. H., Bodewes, R., van den Brand, J. M., de Mutsert, G., Baas, C., van Amerongen, G., Fouchier, R. A., Osterhaus, A. D. & Rimmelzwaan, G. F. (2009). Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27, 4983-4989.
45. Langley, J. M., Carmona Martinez, A., Chatterjee, A., Halperin, S. A., McNeil, S., Reisinger, K. S., Aggarwal, N., Huang, L. M. & Peng, C. T. (2013). Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis 208, 544-553.
46. Lee, L. Y., Ha, L. A., Simmons, C., de Jong, M. D., Chau, N. V., Schumacher, R., Peng, Y. C., McMichael, A. J. & Farrar, J. J. (2008). Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118, 3478-3490.
47. Lindstrom, S. E., Hiromoto, Y., Nishimura, H., Saito, T., Nerome, R. & Nerome, K. (1999). Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes. J Virol 73, 4413-4426.
48. Lundegaard, C., Nielsen, M. & Lund, O. (2006). The validity of predicted T-cell epitopes. Trends Biotechnol 24, 537-538.
49. McCullers, J. A., Saito, T. & Iverson, A. R. (2004). Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol 78, 12817-12828.
50. McMichael, A. J., Gotch, F. M., Noble, G. R. & Beare, P. A. (1983). Cytotoxic T-cell immunity to influenza. N Engl J Med 309, 13-17.
51. O’Neill, E., Krauss, S. L., Riberdy, J. M., Webster, R. G. & Woodland, D. L. (2000). Heterologous protection against lethal A/HongKong/ 156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81, 2689-2696.
52. Olson, D. R., Heffernan, R. T., Paladini, M., Konty, K., Weiss, D. & Mostashari, F. (2007). Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med 4, e247.
53. Paiva, T. M., Benega, M. A., Silva, D. B., Santos, K. C., Cruz, A. S., Hortenci, M. F., Barbieri, M. T., Monteiro, M. M., Barbosa, H. A. & Carvalhanas, T. R. (2013). Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: implications for vaccine composition strategy. J Med Virol 85, 1983-1989.
54. Pérez-Girón, J. V., Belicha-Villanueva, A., Hassan, E., Gómez- Medina, S., Cruz, J. L., Lüdtke, A., Ruibal, P., Albrecht, R. A., García-Sastre, A. & Muñoz-Fontela, C. (2014). Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J Immunol 193, 1324-1332.
55. Quinones-Parra, S., Grant, E., Loh, L., Nguyen, T. H., Campbell, K. A., Tong, S. Y., Miller, A., Doherty, P. C. & Vijaykrishna, D. (2014). Preexisting CD8+T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci U S A 111, 1049-1054.
56. Rimmelzwaan, G. F., Baars, M., Claas, E. C. & Osterhaus, A. D. (1998). Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74,57-66.
57. Rimmelzwaan, G. F., Nieuwkoop, N., Brandenburg, A., Sutter, G., Beyer, W. E., Maher, D., Bates, J. & Osterhaus, A. D. (2000). A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19, 1180-1187.
58. Rimmelzwaan, G. F., deJong, J. C., Bartelds, A. I., Wilbrink, B., Fouchier, R. A. & Osterhaus, A. D. (2003). [The 2001/2002 influenza season and the vaccine composition for the 2002/ season]. Ned Tijdschr Geneeskd 146, 1846-1850 (in Dutch).
59. Robbins, P. A., Lettice, L. A., Rota, P., Santos-Aguado, J., Rothbard, J., McMichael, A. J. & Strominger, J. L. (1989). Comparison between two peptide epitopes presented to cytotoxic T lymphocytes by HLA-A2.Evidence for discrete locations within HLA-A2. J Immunol 143,4098-4103.
60. Robbins, P. A., Garboczi, D. N. & Strominger, J. L. (1995). HLA- A*0201 complexes with two 10-Mer peptides differing at the P2 anchor residue have distinct refolding kinetics. J Immunol 154, 703-709.
61. Robbins, P. A., Rota, P. A. & Shapiro, S. Z. (1997). A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules. Int Immunol 9, 815-823.
62. Roider, J., Meissner, T., Kraut, F., Vollbrecht, T., Stirner, R., Bogner, J. R. & Draenert, R. (2014). Comparison of experimental fine-mapping to in silico prediction results of HIV-1 epitopes reveals ongoing need for mapping experiments. Immunology 143, 193-201.
63. Rota, P. A., Wallis, T. R., Harmon, M. W., Rota, J. S., Kendal, A. P. & Nerome, K. (1990). Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175, 59-68.
64. Rota, P. A., Hemphill, M. L., Whistler, T., Regnery, H. L. & Kendal, A. P. (1992). Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 73, 2737-2742.
65. Russell, C. A., Jones, T. C., Barr, I. G., Cox, N. J., Garten, R. J., Gregory, V., Gust, I. D., Hampson, A. W. & Hay, A. J. (2008). Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26 (Suppl 4), D31-D34.
66. Shaw, M. W., Xu, X., Li, Y., Normand, S., Ueki, R. T., Kunimoto, G. Y., Hall, H., Klimov, A., Cox, N. J. & Subbarao, K. (2002). Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303, 1-8.
67. Silver, M. L., Parker, K. C. & Wiley, D. C. (1991). Reconstitution by MHC-restricted peptides of HLA-A2 heavy chain with beta 2-microglobulin, in vitro. Nature 350, 619-622.
68. Simonsen, L., Clarke, M. J., Williamson, G. D., Stroup, D. F., Arden, N. H. & Schonberger, L. B. (1997). The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 87, 1944-1950.
69. Slepushkin, A. N. (1959). The effect of a previous attack of A1 influenza on susceptibility to A2 virus during the 1957 outbreak. Bull World Health Organ 20, 297-301.
70. Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. & Fouchier, R. A. (2004). Mapping the antigenic and genetic evolution of influenza virus. Science 305, 371-376.
71. Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J. J. & Lalvani, A. (2013). Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 19, 1305-1312.
72. Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J. & Fukuda, K. (2003). Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289,179-186.
73. Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Bridges, C. B., Cox, N. J. & Fukuda, K. (2004). Influenza-associated hospitalizations in the United States. JAMA 292, 1333-1340.
74. Tinoco, J. C., Pavia-Ruz, N., Cruz-Valdez, A., Aranza Doniz, C., Chandrasekaran, V., Dewe´, W., Liu, A., Innis, B. L. & Jain, V. K. (2014). Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ¢18 years: a phase III, randomized trial. Vaccine 32, 1480-1487.
75. Ulmer, J. B. (2002). Influenza DNA vaccines. Vaccine 20 (Suppl 2), S74-S76.
76. van de Sandt, C. E., Kreijtz, J. H. & Rimmelzwaan, G. F. (2012). Evasion of influenza A viruses from innate and adaptive immune responses. Viruses 4, 1438-1476.
77. van de Sandt, C. E., Kreijtz, J. H., de Mutsert, G., Geelhoed-Mieras, M. M., Hillaire, M. L., Vogelzang-van Trierum, S. E., Osterhaus, A. D., Fouchier, R. A. & Rimmelzwaan, G. F. (2014a). Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virus. J Virol 88, 1684-1693.
78. van de Sandt, C. E., Kreijtz, J. H., Geelhoed-Mieras, M. M., Vogelzang-van Trierum, S. E., Nieuwkoop, N. J., van de Vijver, D. A., Fouchier, R. A., Osterhaus, A. D., Morein, B. & Rimmelzwaan, G. F. (2014b). Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine. Vaccine 32,5614-5623.
79. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M. & Melief, C. J. (1996). Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 156, 3308-3314.
80. Weinfurter, J. T., Brunner, K., Capuano, S. V. III, Li, C., Broman, K. W., Kawaoka, Y. & Friedrich, T. C. (2011). Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog 7, e1002381.
81. Westgeest, K. B., de Graaf, M., Fourment, M., Bestebroer, T. M., van Beek, R., Spronken, M. I., de Jong, J. C., Rimmelzwaan, G. F. & Russell, C. A. (2012). Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution. J Gen Virol 93, 1996-2007.
82. WHO (2014a). WHO Recommendations on the Composition of Influenza Virus Vaccines. http://www.who.int/influenza/vaccines/ virus/recommendations/en
83. WHO (2014b). Influenza (Seasonal) Fact Sheet 211. http://www.who.int/mediacentre/factsheets/fs211/en/index.html
84. Yewdell, J. W., Bennink, J. R., Smith, G. L., & Moss, B. (1985). Influenza A virus nucleoprotein is a major target antigen for cross- reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 82, 1785-1789.